What To Know
- “It has been a privilege to work alongside the ViewRay team, and I believe that MRIdian is unequivocally the future of radiation oncology,”.
- “Departing ViewRay is difficult, but I am confident that the team we have built will execute on the opportunity to become standard of care.
Shahriar Matin was named Chief Executive Officer designate of Cordis in its recently announced divestiture from Cardinal Health to private equity firm Hellman & Friedman.
“It has been a privilege to work alongside the ViewRay team, and I believe that MRIdian is unequivocally the future of radiation oncology,” said Shahriar Matin, Chief Operating Officer. “Departing ViewRay is difficult, but I am confident that the team we have built will execute on the opportunity to become standard of care.”
“I would like to thank Shar for his many contributions to ViewRay and cancer patients. I wish him continued success and hearty congratulations in his new endeavors,” said President and Chief Executive Officer Scott Drake. “We have been working closely with Shar to prepare for his departure since last summer when we modified his separation agreement. Given the strength of our team, we are not backfilling the COO role.”